New Ray Medicine International Holding Ltd.
6108.HK
Hong Kong Stock Exchange0.21
HKD
- -
- -
New Ray Medicine International Holding Ltd.
6108.HK
(Hong Kong Stock Exchange)
Recent
price
0.21
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- New Ray Medicine International Holding Limited engages in the distribution and trading of pharmaceutical and related products and provides marketing and promotion services for drugs and chemical reagents for pharmaceutical use. The company operates through two primary segments: Distribution and trading of pharmaceutical and related products; and Provision of marketing and promotion services. It also develops, markets, and promotes a portfolio of pharmaceutical products, chemical reagents, and related healthcare services across its target markets. Headquarters are in Bermuda, and it maintains operations in the PRC (People’s Republic of China) and Hong Kong, reflecting a cross-border distribution and promotional footprint. The company was founded in 2001 and subsequently incorporated in Bermuda; its business scope includes obtaining distribution rights for pharmaceutical products, promoting and marketing activities, and offering related medical network and ancillary services as part of its broader healthcare distribution platform. Subsidiaries and partner arrangements support its regional activities and channel reach. Foundational and structural details - Founding year: 2001; Incorporation in Bermuda - Headquarters: Bermuda - Primary business activity: Distribution and trading of pharmaceutical products; marketing and promotion services for drugs and chemical reagents - Geographic footprint: PRC (including Zhejiang province), Hong Kong, and Bermuda with regional distribution networks Main products and services (core offerings) - Core pharmaceutical products: levocarnitine injections; thoymosin α1 injections; other injectable therapeutics such as cefamandole nafate, ceftizoxime sodium, and isepamicin sulfate injections used for respiratory, genitourinary, intra-abdominal, orthopedic, and septic conditions - Chemical reagents and related products: chemical reagents for pharmaceutical use; recombinant cytokine gene-derived protein injections; other pharmaceutical raw materials and reagents - Marketing and promotion services: promotional campaigns, product launch activities, physician and hospital network engagement, and related marketing support for pharmaceutical products and chemical reagents - Ancillary services: third-party medical network administration, medical and dental service provision, hospital management support, and property leasing tied to the healthcare platform Latest major company changes (within the last 1–2 years) - Strategic expansion in product portfolio: launch of a chemical reagents for pharmaceutical products in the PRC in 2024, signaling diversification beyond traditional drug distributions - Revenue and segment changes: continued growth in distribution and trading alongside expanded promotion services, with notable increases in segment revenue driven by new product launches and broader market penetration - Corporate and regulatory filings: regular reporting updates through Hong Kong stock exchange and Bermuda disclosures detailing segment performance, changes in product mix, and strategic initiatives, including improvements in distribution rights acquisitions and marketing capabilities - Ongoing partnerships and alliances: continued collaborations with pharmaceutical manufacturers and a network of distributors to broaden geographic coverage and service offerings - Operational enhancements: enhancements to the group’s marketing and promotion capabilities and regulatory compliance posture in PRC markets, aligning with expanded product lines and territories Industry context and company positioning - Industry: Pharmaceutical distribution and marketing services - Segments: Distribution and trading of pharmaceutical products; marketing and promotion services - Target markets: PRC pharmaceutical manufacturers, hospitals, and clinics; regional distributors; healthcare networks in Hong Kong and PRC - Growth trajectory: diversification into chemical reagents and allied healthcare services to complement core drug distribution; expansion of promotional services to support product launches and network development Note: Information reflects publicly disclosed materials available through corporate filings and reputable market data sources, with emphasis on the company’s stated product categories, regional operations, and recent strategic shifts.